Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Warner Huh

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Journal of Lower Genital Tract Disease|March 6, 2024
Recommendations for Use of p16/Ki67 Dual Stain for Management of Individuals Testing Positive for Human PapillomavirusMegan A Clarke, Nicolas Wentzensen, Rebecca B Perkins, et al.
Gynecologic Oncology|January 6, 2023
Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivorsCynthia A Thomson, Tracy E Crane, Austin Miller, et al.
Pediatrics|July 17, 2016
Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical TrialsEdson D Moreira, Stan L Block, Daron Ferris, et al.
Papillomavirus Research (Amsterdam, Netherlands)|July 20, 2017
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trialsLone K Petersen, Jaime Restrepo, Edson D Moreira, et al.
Cancer Causes & Control : CCC|July 6, 2013
Recommendations for a national agenda to substantially reduce cervical cancerJennifer S Smith, Noel T Brewer, Debbie Saslow, et al.
Papillomavirus Research (Amsterdam, Netherlands)|October 28, 2017
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by regionXavier Castellsagué, Kevin A Ault, F Xavier Bosch, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2014
Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical diseaseElmar A Joura, Kevin A Ault, F Xavier Bosch, et al.
The Lancet. Oncology|November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialCosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
The New England Journal of Medicine|February 19, 2015
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in womenElmar A Joura, Anna R Giuliano, Ole-Erik Iversen, et al.
The Journal of Infectious Diseases|October 5, 2013
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observationAnne Szarewski, S Rachel Skinner, Suzanne M Garland, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Lower Genital Tract Disease|March 6, 2024
Recommendations for Use of p16/Ki67 Dual Stain for Management of Individuals Testing Positive for Human PapillomavirusMegan A Clarke, Nicolas Wentzensen, Rebecca B Perkins, et al.
Gynecologic Oncology|January 6, 2023
Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivorsCynthia A Thomson, Tracy E Crane, Austin Miller, et al.
Pediatrics|July 17, 2016
Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical TrialsEdson D Moreira, Stan L Block, Daron Ferris, et al.
Papillomavirus Research (Amsterdam, Netherlands)|July 20, 2017
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trialsLone K Petersen, Jaime Restrepo, Edson D Moreira, et al.
Cancer Causes & Control : CCC|July 6, 2013
Recommendations for a national agenda to substantially reduce cervical cancerJennifer S Smith, Noel T Brewer, Debbie Saslow, et al.
Papillomavirus Research (Amsterdam, Netherlands)|October 28, 2017
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by regionXavier Castellsagué, Kevin A Ault, F Xavier Bosch, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2014
Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical diseaseElmar A Joura, Kevin A Ault, F Xavier Bosch, et al.
The Lancet. Oncology|November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialCosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
The New England Journal of Medicine|February 19, 2015
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in womenElmar A Joura, Anna R Giuliano, Ole-Erik Iversen, et al.
The Journal of Infectious Diseases|October 5, 2013
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observationAnne Szarewski, S Rachel Skinner, Suzanne M Garland, et al.
Pageof 4